ArticleChemical science2018
Forming next-generation antibody-nanoparticle conjugates through the oriented installation of non-engineered antibody fragments.
Article in Chemical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Antibody Conjugation Strategies for Ultrasound Microbubbles: A Review of Bioconjugation Chemistry and Clinical Translation.Ultrasound in medicine & biology · 2026Review
- Entry Without Expression: Internalisation Does Not Predict mRNA Translation for Targeted Lipid Nanoparticles.Small science · 2026Article
- Engineering extracellular vesicles for targeted therapeutic delivery in the heart.Bioscience reports · 2026Review
- Utilizing Constrained Bicyclic Peptides forACS nano · 2026Article
- Development of Novel Neratinib and Docetaxel Core-Loaded and Trastuzumab Surface-Conjugated Nanoparticle for Treatment of HER-2 Positive Breast Cancer.Pharmaceutics · 2025Article
- Multifunctional Magnetic Ionic Liquid-Carbon Nanohorn Complexes for Targeted Cancer Theranostics.Small science · 2025Article
- Magnetic-Plasmonic Core-Shell Nanoparticles: Properties, Synthesis and Applications for Cancer Detection and Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Adapting Ferritin, a Naturally Occurring Protein Cage, to Modulate Intrinsic Agonism of OX40.Bioconjugate chemistry · 2024Article
- Approaches to Characterize and Quantify Extracellular Vesicle Surface Conjugation Efficiency.Life (Basel, Switzerland) · 2024Review
- Nanomaterials as a Potential Target for Infectious Parasitic Agents.Current drug delivery · 2024Review
- Development of a cationic polyethyleneimine-poly(lactic-RSC advances · 2023Article
- pH and NaCl Optimisation to Improve the Stability of Gold and Silver Nanoparticles' Anti-Zearalenone Antibody Conjugates for Immunochromatographic Assay.Methods and protocols · 2023Article
- Recent Advances in Cell Membrane Coated-Nanoparticles as Drug Delivery Systems for Tackling Urological Diseases.Pharmaceutics · 2023Review
- Optimizing Conjugation Chemistry, Antibody Conjugation Site, and Surface Density in Antibody-Nanogel Conjugates (ANCs) for Cell-Specific Drug Delivery.Bioconjugate chemistry · 2023Article
- Nanoparticle Targeting with Antibodies in the Central Nervous System.BME frontiers · 2023Review
- Modification of Fab Fragments by Dibromopyridazinediones Carrying Mono- and Double-Biotin Functionalities.ACS omega · 2022Article
- Hybrid Molecularly Imprinted Polymers: The Future of Nanomedicine?Nanomaterials (Basel, Switzerland) · 2021Review
- Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.Biochemical Society transactions · 2021Review
- Site-selective lysine conjugation methods and applications towards antibody-drug conjugates.Chemical communications (Cambridge, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The successful development of targeted nanotherapeutics is contingent upon the conjugation of therapeutic nanoparticles to target-specific ligands, with particular emphasis being placed on antibody-based ligands. Thus, new methods that enable the covalent and precise installation of targeting antibodies to nanoparticle surfaces are greatly desired, especially those which do not rely on costly and time-consuming antibody engineering techniques. Herein we present a novel method for the highly controlled and oriented covalent conjugation of non-engineered antibody F(ab) fragments to PLGA-PEG nanoparticles using disulfide-selective pyridazinedione linkers and strain-promoted alkyne-azide click chemistry. Exemplification of this method with trastuzumab and cetuximab showed significant improvements in both conjugation efficiency and antigen binding capability, when compared to commonly employed strategies for antibody-nanoparticle construction. This new approach paves the way for the development of antibody-targeted nanomedicines with improved paratope availability, reproducibility and uniformity to enhance both biological activity and ease of manufacture.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.